Windtree Financial Report from Smith On Stocks

Friday, June 30, 2017 · 10:05 am

Tuesday, June 13, 2017 · 1:21 pm

Wednesday, May 24, 2017 · 3:49 pm

Tuesday, January 3, 2017 · 10:18 am

Tuesday, October 25, 2016 · 2:52 pm

Thursday, May 12, 2016 · 5:41 pm

Monday, April 4, 2016 · 1:26 pm

Thursday, February 4, 2016 · 9:11 am

Friday, November 13, 2015 · 11:48 am

Tuesday, August 11, 2015 · 12:39 pm

Monday, July 20, 2015 · 9:42 am

Tuesday, June 23, 2015 · 8:02 am

Thursday, April 16, 2015 · 7:46 am

Tuesday, December 2, 2014 · 10:09 am

Thursday, August 14, 2014 · 9:07 am

Thursday, May 29, 2014 · 10:38 am

Monday, November 18, 2013 · 10:44 am

Friday, October 4, 2013 · 12:45 pm

Thursday, March 21, 2013 · 1:34 pm

Thursday, February 14, 2013 · 9:25 am

Monday, December 17, 2012 · 10:40 am

Thursday, May 31, 2012 · 1:01 pm

Sunday, April 8, 2012 · 11:24 am

Sunday, April 8, 2012 · 11:04 am

There are 24 reports on file.

Reports on Windtree

Reports on Windtree

Recent Reports

Windtree Therapeutics: Phase 2b Trial Fails Although There Was An Encouraging Signal of Activity (WINT, Take tax loss, $0.34)

Windtree Therapeutics: Discussion of Licensing Deal with Lee�s Pharmaceutical and Two Imminent Key Clinical Events (WINT, Buy, $0.90)

Windtree Therapeutics: Thinking About the Stock Price After Phase 2b Results for Aerosurf in RDS Are Released In July (WINT, $0.92)

SmithOnStocks Top Stock Picks for 2017, January 3, 2017

Windtree Therapeutics (WINT, Take Tax Loss, $2.50): Critical Aerosurf Phase 2b Trial Completion is Delayed; Can the Company Raise the Capital Needed to Complete the Trial

Windtree Therapeutics: Key Points from Conference Call on 1Q, 2016 Results (WINT, $2.04)

Discovery Laboratories: Clinical Trial Data over Next Year Could Validate the Promise of Aerosurf (DSCO, Buy, $1.60)

Discovery Laboratories: New CEO and Update on Aerosurf (DSCO, $2.26)

Discovery Laboratories: Results for Aerosurf in Phase 2a Trial are Encouraging; Why Then Did the Stock Crash? (DSCO, Buy, $0.30)

Discovery Laboratories: Update from the 2Q, 2015 Conference Call Provides Timelines for Important Aerosurf Phase 2 Trials (DSCO, Buy, $0.47)

Discovery Laboratories: What I Intend to Do in the Aftermath of a Disastrous Stock Offering (DSCO, Buy, $0.54)

Discovery Laboratories: An Analysis of Phase 2a Results for Aerosurf and What to do with the Stock (DSCO, $0.81, for paid subscribers)

Discovery Laboratories: Focus is Totally on Aerosurf Development (DSCO, $1.43, Hold)

Discovery Laboratories: Delay in Completion of Aerosurf Phase 2a Trial and Continued Disappointing Sales of Surfaxin Weigh on the Stock (DSCO, $1.53, Hold)

Discovery Laboratories: My Current Thinking on the Surfaxin Launch and Aerosurf Phase 2 Trials (DSCO, Buy/Hold, $1.62)

Discovery Laboratories: An Update on the Surfaxin Launch and the Phase 2 Clinical Trial Program for Aerosurf (DSCO, Buy, $1.72)

Discovery Laboratories (DSCO, $2.07): An Asymmetric Opportunity

Discovery Laboratories: What the Marketing Approval of Surfaxin Could Mean to the Stock (DSCO, $2.72)

Discovery Laboratories: The Surfaxin Launch and Beyond (DSCO, $2.38)

Discovery Laboratories: Innovative Financing is a Catalyst to Buy the Stock (DSCO, $2.16)

Discovery Laboratories: Disappointment with the Delay in the Surfaxin Launch Has Created a Buying Opportunity (DSCO, $2.24)

Discovery Laboratories: Surfaxin Is Superior to Animal Surfactants (DSCO, $2.74)

Equity Offering Provides Discovery Laboratories Much Needed Financial Strength (DSCO, $2.81)

Surfaxin Should Be Approved on its March 6th PDUFA Date (DSCO, $2.82)